+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Company Analysis: Kyowa Kirin

  • Company Profile
  • 38 Pages
  • January 2021
  • Pharma Intelligence
  • ID: 5357326
The publisher explores Kyowa Kirin’s prescription pharmaceutical performance and outlook over 2019-29.

Snapshot

  • Overview - Kyowa Kirin’s late-stage pipeline and exposure to generics mean an increased reliance on new product revenue.
  • Key themes - [1] Kyowa Kirin revenue continues to be negatively impacted by branded and generic competition to its portfolio of longer-listed products [2] Kyowa Kirin is combating these sales declines and providing Rx sales growth through its new products such as Orkedia, which is a successor to long-listed product Regpara, and finding opportunities elsewhere with a rituximab biosimilar and growth through overseas activity with Crysvita, Poteligeo, and Nouriast.

Model updates (30 October 2020)

  • Nesp forecast adjusted lower due to biosimilar competition
  • Crysvita forecast adjusted higher.

Model updates (31 October 2019)

  • Biosimilar rituximab forecast adjusted higher due to strong sales growth
  • Nouriast forecast adjusted for US launch
  • Other Revenue forecast adjusted lower due to the sale of Kyowa Hakko Bio.

Model updates (14 August 2019)

  • Crysvita forecast adjusted higher due to strong post-launch results in North America
  • Orkedia forecast adjusted higher due to strong reported sales growth
  • Poteligeo forecast adjusted higher due to strong US market penetration from successful launch
  • Allelock forecast adjusted lower due to increased generic competition
  • Abstral forecast adjusted lower due to Brexit issues.

Table of Contents

Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison

Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis

Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights

Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug